Dr Reddys Laboratories Ltd
DRREDDYDr Reddys Laboratories Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: Domestic institutions moved +11.0 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced.
The price is in a downtrend (6 weeks in) while the P/E sits at the 60th percentile of its own 11-year range. Underneath, the last four quarters read deteriorating — profit −69.1% year on year, and 96% of the last 3 years' profit arrived as cash. What settles it: whether the register turns back in the story’s favour.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Dr Reddys Laboratories Ltd trades at ₹1,166, in a downtrend and 6 weeks into that stage. That is −5.9% against its own 200-day average. It sits at 8% of a 52-week range of ₹1,148 to ₹1,374. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (11 weeks and counting).
Today the stock is in a downtrend — week 6 of stage 4, confirmed. At ₹1,166 it trades −5.9% versus its 200-day average and sits at 8% of its 52-week range (₹1,148–₹1,374).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +79% while the NIFTY 500 moved +264% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (11 weeks and counting; last ahead the week of 2026-07-01) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Story check
Dr Reddys Laboratories Ltd's story is not scored yet against the markers our research file set on 17 May 2026. Where it sits in its own cycle: CYCLE_BOTTOM_TO_RECOVERY. Our fortnightly research layers last read it on 27 June 2026.
Our read, 17 May 2026. Lenalidomide cliff absorbed in Q4 — the next earnings base is clean and three converging catalysts (Semaglutide scale, Abatacept US launch, India +16%) are now the story.
From the numbers. PE at 19.4x, 21st percentile of 10-year history (median 25.3x, ratio 0.767). CYCLE_BOTTOM classification with INFLECTION_UP yoy_trend. Two historical PE peaks: 44.8x Dec 2016 and 44.2x Mar 2021. Currently in a trough…
From the price. Price stage 4, week 6 — below its 200-day line, relative strength flat.
From the research. Lenalidomide cliff absorbed in Q4 — the next earnings base is clean and three converging catalysts (Semaglutide scale, Abatacept US launch, India +16%) are now the story.
🚨 Where they disagree. PE at 19.4x, 21st percentile of 10-year history (median 25.3x, ratio 0.767). CYCLE_BOTTOM classification with INFLECTION_UP yoy_trend. Two historical PE peaks: 44.8x Dec 2016 and 44.2x Mar 2021. Currently in a trough driven by Lenalidomide transition earnings compression — not structural business deterioration. FII selling (22.34% Dec 2025 vs 26.99% Jun 2023) suppresses re-rating despite DII accumulation (30.44% Dec 2025 vs 18.65% Dec 2023). Re-rating trigger: Q1 FY27 clean earnings base + visible Semaglutide contribution.
What is proven. Lenalidomide cliff absorbed in Q4 — the next earnings base is clean and three converging catalysts (Semaglutide scale, Abatacept US launch, India +16%) are now the story.
What is not proven yet. Management already walked back 12M pen certainty to 10–11M, then 6–7M by end CY26. Brazil ANVISA delay adds uncertainty. If net pricing compresses below $25/unit on competitive intensity, PAT contribution thins materially.
🚨 Layer 1 read, 27 June 2026 — DROP. Held large-cap pharma in a Lenalidomide-cliff earnings air-pocket — the Q4 crash is a one-off charge, but the recovery rests on walked-back catalysts. Q4 OPM fell to 5% and EPS to ₹2.65, but that is a disclosed ₹453 Cr Lenalidomide shelf-stock one-off, not an operating collapse — adjusted EBITDA held at 19.5% and the base grew double digits. The problem is structural: North America is down 21% as finite Lenalidomide profit exits, and the recovery depends on Semaglutide and Abatacept that management has already walked back and slipped, with the timeline validation FAILED.
What would change Layer 1’s mind. Q1 FY27 (Aug 2026) gross margin failing to recover toward 50% AND Semaglutide showing <2.5M cumulative pens or another Abatacept slip — that would confirm the NA step-down is not being offset by the new drivers, turning the air-pocket into a structural de-rating and flipping this to DROP/exit; conversely a clean gross-margin snap-back with Semaglutide on-track validates the hold.
🚨 CIO read, 27 June 2026 — EXIT. EXIT · forward-asymmetry 40/100 · CONTESTED.
The test written in advance. Semaglutide volume/margin delivery misses FY27 targets — Semaglutide volume/margin delivery misses FY27 targets Q1 FY27 concall (Aug 2026): actual CY26 unit delivery vs 6–7M target; gross margin per unit disclosure by the next result.
The test written in advance. Abatacept FDA timeline slips further / Bachupally inspection fails — Abatacept FDA timeline slips further / Bachupally inspection fails FDA inspection announcement for Bachupally facility; any Form 483 disclosure in Q1 FY27 concall by the next result.
The test written in advance. Management consistency pattern — guidance credibility erosion — Management consistency pattern — guidance credibility erosion Q1 FY27 actual NA revenue vs 'double-digit ex-Lena' commitment; Semaglutide actual unit delivery vs 6–7M target by the next result.
What the company does. Q4 FY26 was peak pain: adjusted EBITDA held at 19.5% margin despite a Rs 453 Cr shelf-stock adjustment from the Lenalidomide cliff — underlying base business grew double digits throughout. PE at 21st percentile (ratio 0.767x median, cycle_position = CYCLE_BOTTOM) while FY27 has three new PAT drivers: 6–7M Semaglutide pens CY26, Abatacept IV launch early CY27, and India outpacing IPM by 240–300 bps. Management credibility is mixed — four documented consistency failures — but the structural thesis (Lenalidomide was finite; biosimilar/GLP-1 pipeline is not) is unchanged and measurable.
| Dial | Now | Was | Why it matters | Watch line |
|---|---|---|---|---|
| Semaglutide (GLP-1) Global Ramp… | HIGH | — | Canada first-mover approval secured; Obeda launched in India on patent expiry; 6–7M units target CY26, 12M FY27, 50+ markets… | Q1 FY27 concall (Aug 2026): actual CY26 unit delivery vs 6–7M target; gross margin per unit disclosure |
| Abatacept IV Biosimilar — First-to-File… | HIGH | — | BLA accepted Feb 2026 (first-to-submit); launch expected early CY27; Bachupally FDA inspection pending. European launch already… | Q1 FY27 concall (Aug 2026): actual CY26 unit delivery vs 6–7M target; gross margin per unit disclosure |
| India Business — Structural Market Share… | MEDIUM_HIGH | — | India FY26 +16% (Q4 +20%), IPM outperformance 240–300 bps; ranked 9th nationally. 28 new brand launches FY26. Entry into HRT… | Q1 FY27 concall (Aug 2026): actual CY26 unit delivery vs 6–7M target; gross margin per unit disclosure |
| Emerging Markets — Volume Growth +… | MEDIUM | — | EM FY26 Rs 6,761 Cr (+23%). Russia +8% YoY constant currency (down 23% QoQ sequential — timing/FX). 49 new products in Q4, 129… | Q1 FY27 concall (Aug 2026): actual CY26 unit delivery vs 6–7M target; gross margin per unit disclosure |
| North America Base Business Recovery — 27… | MEDIUM | — | 27 new product launches planned FY27 including Bosutinib; management committed to double-digit NA ex-Lenalidomide growth for… | Q1 FY27 concall (Aug 2026): actual CY26 unit delivery vs 6–7M target; gross margin per unit disclosure |
| NRT Integration + European Consumer Health… | MEDIUM | — | NRT operational integration 85%+ complete; delivered 16% growth in Q4 (though partly transition stock-loading); European… | Q1 FY27 concall (Aug 2026): actual CY26 unit delivery vs 6–7M target; gross margin per unit disclosure |
Lever 11 · Selling more to existing customers — BUILDING. Canada first-mover approval secured; Obeda launched in India on patent expiry; 6–7M units target CY26, 12M FY27, 50+ markets within CY26. Net price $25–30/unit floor. FY28 capacity 40M+ on FTO-11 qualification. What proves it keeps working: Semaglutide (GLP-1) Global Ramp — First-Mover in Canada, India. It stops working if Q1 FY27 concall (Aug 2026): actual CY26 unit delivery vs 6–7M target; gross margin per unit disclosure.
Lever 15 · Market-share gains — BUILDING. India FY26 +16% (Q4 +20%), IPM outperformance 240–300 bps; ranked 9th nationally. 28 new brand launches FY26. Entry into HRT segment with Proginova/Cyclo-Proginova acquisition. What proves it keeps working: India Business — Structural Market Share Gains, Innovation Franchise. It stops working if Q1 FY27 concall (Aug 2026): actual CY26 unit delivery vs 6–7M target; gross margin per unit disclosure.
Lever 10 · New geographies — BUILDING. EM FY26 Rs 6,761 Cr (+23%). Russia +8% YoY constant currency (down 23% QoQ sequential — timing/FX). 49 new products in Q4, 129 full-year. Geographic diversification strategy delivering. What proves it keeps working: Emerging Markets — Volume Growth + Geographic Diversification. It stops working if Q1 FY27 concall (Aug 2026): actual CY26 unit delivery vs 6–7M target; gross margin per unit disclosure.
Lever 3 · Management change — BUILDING. 27 new product launches planned FY27 including Bosutinib; management committed to double-digit NA ex-Lenalidomide growth for FY27. FTO-2 VAI classification in March 2026 supports commercial readiness. What proves it keeps working: North America Base Business Recovery — 27 New Launches, Bosutinib. It stops working if Q1 FY27 concall (Aug 2026): actual CY26 unit delivery vs 6–7M target; gross margin per unit disclosure.
Sources: our stock research file (17 May 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Dr Reddys Laboratories Ltd reported ₹8,100 Cr of revenue in the Jun 26 quarter, −5.5% year on year. Over 10 years it has compounded at 8.0% a year. The last full year, FY26, came in at ₹33,700 Cr. The last four reported quarters add to ₹33,227 Cr.
Why this happened. Semaglutide is the single most important new revenue driver for the next 3 years. Health Canada approval for injectable semaglutide gives Dr Reddy's first-mover advantage in a market where the originator (Novo Nordisk) commands premium pricing. India launched as Obeda on November 2025 patent expiry. The near-term geometry: 6–7 million units by end CY26 (across approved + about-to-approve markets), ramping to 12M in FY27, with potential 40M+ per year upon FTO-11 qualification in FY28. Pricing: list price ~50% of Novo, net realization $25–30/unit in most markets (higher in premium geographies). Brazil remains a near-term risk (ANVISA review, 3–4 month delay confirmed) but management retains…
FY26 revenue came in at ₹33,700 Cr (+3.2% on the year), capping 10 years at 8.0% compound. The latest quarter (Jun 26) printed ₹8,100 Cr, −5.5% year on year.
Pace check: the last four quarters averaged −0.7% growth against the decade's 8.0% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −0.9% over the last 4 quarters against +7.1%/yr over the last 8 — rolling over; TTM profit −44.6% vs −24.4%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Dr Reddys Laboratories Ltd's operating margin is 11.0% in the Jun 26 quarter, −14.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 14.0% to 28.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 11.0%, −14.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 14.0%–28.0%.
🚨 Why the margin moved: operating margin went −14.7 pp year on year while gross margin went −9.0 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Dr Reddys Laboratories Ltd earned ₹436 Cr of net profit in the Jun 26 quarter, −69.1% year on year. Full-year FY26 profit was ₹4,158 Cr. The 10-year compound rate is 6.9%. That is 5.4% of the quarter's revenue. The same quarter a year earlier earned ₹1,410 Cr.
Jun 26 profit was ₹436 Cr, −69.1% year on year. On the full year, FY26 printed ₹4,158 Cr (−27.4%), and the 10-year compound rate is 6.9%.
🚨 Why profit moved: revenue contributed −5.5% and the margin −14.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −42.7% vs revenue −0.7%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 96% of Dr Reddys Laboratories Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹5,674 Cr of operating cash against ₹4,158 Cr of profit. After ₹4,890 Cr of capital spending, ₹784 Cr was left as free cash.
FY26: operating cash of ₹5,674 Cr against reported profit of ₹4,158 Cr, leaving free cash of ₹784 Cr after ₹4,890 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 96% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 96%: the cash cycle tightened 12 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 3.5× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Dr Reddys Laboratories Ltd's cash conversion cycle runs 247 days in FY26, down from 259 days in FY21. Capital spending ran ₹18,507 Cr over the last 3 years. At FY26 sales of ₹33,700 Cr each day of that cycle holds about ₹92.3 Cr, so roughly ₹22,805 Cr sits inside the business at any moment.
FY26: debtors at 110 days, inventory at 228 days — roughly 7.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 247 days, tighter than FY21's 259.
The full loop: cash goes out to suppliers and production on day 0; stock waits 228 days to sell; customers pay about 110 days after that; and suppliers themselves are paid at 91 days — netting out to the 247-day cycle.
In money terms: at FY26 sales of ₹33,700 Cr, each day of the cycle holds about ₹92.3 Cr — so the 247-day loop keeps roughly ₹22,805 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹18,507 Cr over the last 3 fiscal years against ₹5,233 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹1,460 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Dr Reddys Laboratories Ltd earns a ROCE of 13% in FY26. That is up from a trough of 8% in FY18. Return on invested capital clears the cost of that capital by −4.5 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 12.3% net margin on 0.60× asset turns.
FY26 ROCE is 13%, recovered from a FY18 trough of 8% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 12.3% net margin × 0.60× asset turns × 1.49× balance-sheet leverage ≈ 11.0% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 7.5% − 12.0% = a −4.5 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Dr Reddys Laboratories Ltd carries total debt of ₹7,195 Cr against shareholder equity of ₹38,674 Cr as of Jun 26, a debt-to-equity of 0.19 — effectively unlevered. On the annual view that ratio went from 0.18 in FY22 to 0.20 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Jun 26: total debt of ₹7,195 Cr against shareholder equity of ₹38,674 Cr — a debt-to-equity of 0.19. On the annual view, debt-to-equity went from 0.18 (FY22) to 0.20 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 11.0 points of Dr Reddys Laboratories Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 31.8% of the company. Foreign institutions moved −7.0 points over the same window, to 20.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.
Why this happened. North America was the Lenalidomide story in FY26 — down 21% YoY to $1.36 Bn as the high-margin arrangement unwound. Q4 FY26 revenue $251 Mn ex-SSA (down 40% YoY). The base resets Q1 FY27 onwards. Management committed under direct Q&A pressure to double-digit growth in North America ex-Lenalidomide for FY27 — a reversal from the single-digit guide issued in January 2026 (this is one of the documented consistency concerns). Portfolio refresh: 27 new product launches planned including Bosutinib. Semaglutide is 'on top' of this base. Q1 FY27 will be the first clean read on whether the base business is actually accelerating.
The register over the last two years — Domestic institutions: +11.0 points over 8 quarters to 31.8%; Foreign institutions: −7.0 points over 8 quarters to 20.7%; Promoters: +0.0 points over 8 quarters to 26.6%.
Why the register moved: rotation — foreign institutions −7.0 points against domestic institutions +11.0 points over 8 quarters, with promoters holding steady — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Dr Reddys Laboratories Ltd: the Z-score reads 5.29. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 5.29 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 5.29.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Dr Reddys Laboratories Ltd trades at 30.2× P/E, mid-range by its own standards (60th percentile). Its long-run median P/E is 25.9×, measured across 10.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 30.2× is mid-range by its own standards (60th percentile), against a long-run median of 25.9× measured over 10.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −25.8% against a −11.5% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +3.5%/yr price move, ~+13.0%/yr came from earnings growth and ~−9.5 pp from the multiple (compressing); over 10y, of the +6.2%/yr price move, ~+7.2%/yr came from earnings growth and ~−1.0 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 29 June 2026 price, Dr Reddys Laboratories Ltd was paying for profit growth of about 17.5% a year. Profit itself has compounded 6.9% a year over the past 10 years. Today the market pays 30.2× P/E, the 60th percentile of its own 11-year range.
What the two numbers say together. The multiple is unremarkable against its own past, and the growth the price is paying for is far above what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 29 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Dr Reddys Laboratories Ltd reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −44.6% latest against +64.4% at its 12-quarter best), ROCE slipping at 11.2%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +3.2% | +11.0% | +12.1% | +8.0% |
| Profit | −27.4% | −2.7% | +16.3% | +6.9% |
| EPS | −25.8% | −2.4% | +16.5% | +7.2% |
| Share price | −11.5% | +1.4% | +3.5% | +6.2% |
4-Factor Sector Score
30.1/100 — rank 41 of 44 in Pharma - Formulators · 100% evidence confidence
Dr Reddys Laboratories Ltd scores 30.1 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 41. Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
The four contributions add to the total exactly: 3.7 + 11.7 + 13.3 + 1.4 = 30.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Said versus delivered
What Dr Reddys Laboratories Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
Biologics Sales Figure Is Not Reconciled · 22 July 2026. The January 2026 call described global biologics sales as about US$100 million, whereas the July 2026 Q1 call described biologics as only 2% of overall sales. Because the latest call reported total quarterly revenue of US$853 million, its statement implies roughly US$17 million for the quarter; management did not explain whether the figures use different periods or definitions, creating a material issue for modeling the biologics business and its break-even profile.
FY27 Capex Guidance Reduced · 22 July 2026. The January 2026 call guided to around 2,000 crores for the next year, which corresponds to FY27 after the FY26 year-end call. The latest call now guides to close to 1,800 crores for FY27, a 10% reduction, without explaining the change; its reference to ongoing investments explains the spending need but not the lower amount.
Semaglutide Volume Target Walked Back · 12 May 2026. In both the Oct 2025 and Jan 2026 calls, management expressed strong confidence that 12 million Semaglutide pens would be sold for the relevant fiscal period, with the Jan 2026 call explicitly reaffirming the number as unchanged. In the May 2026 call, management revised this down to 10-11 million for FY27 with the remainder likely spilling into early FY28, and guided to only 6-7 million units by end of calendar 2026, representing a material reduction from a target management had previously described with near-certainty.
🚨 Abatacept IV Approval Timeline Slipped · 12 May 2026. The Jan 2026 call guided for IV Abatacept regulatory approval towards the end of calendar 2026, which would have implied a launch within FY27 on a favorable timeline. The May 2026 call has shifted this to the beginning of calendar 2027, a 3-6 month delay with direct implications for biosimilar revenue contribution timing and the segment's path to breakeven. No specific explanation was provided for what caused the slippage.
Every quote above is taken word for word from the company’s own earnings calls.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Kwality Pharmaceuticals Ltd539997 | 73.7/100Favorable setup82% evidence | LEADER | 31.1/35 Revenue 37.9% · PAT 88.4% · OPM change 3 pp 95% evidence | 17.8/25 ROCE 24.1% · OPM 25% 76% evidence | 6.2/20 P/E 46.3× · PEG — 50% evidence | 18.6/20 RS sector 72.7% · RS bench 113.3% · 1Y 288.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 31.1 + 17.8 + 6.2 + 18.6 = 73.7 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Glenmark Pharmaceuticals LtdGLENMARK | 71.1/100Favorable setup100% evidence | TURNING | 30.8/35 Revenue 32.9% · PAT 100% · OPM change 2 pp 100% evidence | 18.2/25 ROCE 39.8% · OPM 20% 100% evidence | 12.4/20 P/E 21.9× · PEG 1.43 100% evidence | 9.7/20 RS sector -11.1% · RS bench 15.2% · 1Y 17.9%3 of 12 weeks ahead 100% evidence |
| Exact sum: 30.8 + 18.2 + 12.4 + 9.7 = 71.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Bliss GVS Pharma LtdBLISSGVS | 69.5/100Favorable setup82% evidence | LEADER | 29.0/35 Revenue 20.6% · PAT 25.7% · OPM change 7 pp 95% evidence | 14.8/25 ROCE 16.9% · OPM 27% 76% evidence | 6.0/20 P/E 55.7× · PEG — 50% evidence | 19.7/20 RS sector 102.4% · RS bench 147.9% · 1Y 362.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 29 + 14.8 + 6 + 19.7 = 69.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Ipca Laboratories LtdIPCALAB | 67.9/100Favorable setup82% evidence | BREAKING OUT | 26.3/35 Revenue 10.6% · PAT 68% · OPM change 6 pp 95% evidence | 15.8/25 ROCE 17% · OPM 24% 76% evidence | 11.0/20 P/E 36.4× · PEG — 50% evidence | 14.8/20 RS sector -0.6% · RS bench 28.3% · 1Y 47.5%10 of 12 weeks ahead 100% evidence |
| Exact sum: 26.3 + 15.8 + 11 + 14.8 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Lupin LtdLUPIN | 66.8/100Favorable setup93% evidence | ASLEEP | 29.6/35 Revenue 28.2% · PAT 49.2% · OPM change 2 pp 100% evidence | 19.3/25 ROCE 29.9% · OPM 30% 100% evidence | 16.3/20 P/E 16.1× · PEG 0.54 65% evidence | 1.6/20 RS sector -26.2% · RS bench -4% · 1Y 7.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 29.6 + 19.3 + 16.3 + 1.6 = 66.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -26.2% and the one-year return is 7.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 6Emcure Pharmaceuticals LtdEMCURE | 66.3/100Favorable setup75% evidence | LEADER | 27.3/35 Revenue 18.4% · PAT 32.2% · OPM change 1 pp 95% evidence | 18.2/25 ROCE 24% · OPM 21% 76% evidence | 9.9/20 P/E 36.4× · PEG — 15% evidence | 10.9/20 RS sector -2.5% · RS bench 25.5% · 1Y 44.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 27.3 + 18.2 + 9.9 + 10.9 = 66.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Corona Remedies LtdCORONA | 65.2/100Favorable setup73% evidence | BREAKING OUT | 23.0/35 Revenue 18% · PAT 19.3% · OPM change 2 pp 100% evidence | 20.4/25 ROCE 33.3% · OPM 22% 100% evidence | 11.8/20 P/E 64.4× · PEG 1.18 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 23 + 20.4 + 11.8 + 10 = 65.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Fredun Pharmaceuticals LtdFREDUN | 64.9/100Mixed-positive evidence74% evidence | 26.7/35 Revenue 91.5% · PAT 100% · OPM change 0 pp 95% evidence | 13.0/25 ROCE 21.3% · OPM 14% 95% evidence | 9.3/20 P/E 53.3× · PEG — 15% evidence | 15.9/20 RS sector 24.1% · RS bench 96.2% · 1Y 9.2%4 of 12 weeks ahead 70% evidence | |
| Exact sum: 26.7 + 13 + 9.3 + 15.9 = 64.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Accent Microcell LtdACCENTMIC | 64.5/100Mixed-positive evidence63% evidence | LEADER | 17.5/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 18.9/25 ROCE 24.9% · OPM 16% 95% evidence | 8.7/20 P/E 39.7× · PEG — 50% evidence | 19.4/20 RS sector 44.8% · RS bench 83.4% · 1Y 160.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 18.9 + 8.7 + 19.4 = 64.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Caplin Point Laboratories LtdCAPLIPOINT | 61.8/100Mixed-positive evidence100% evidence | LEADER | 19.0/35 Revenue 15% · PAT 19.6% · OPM change 0 pp 100% evidence | 17.7/25 ROCE 24.2% · OPM 35% 100% evidence | 9.4/20 P/E 31.5× · PEG 1.52 100% evidence | 15.7/20 RS sector 5.8% · RS bench 36.1% · 1Y 28.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 17.7 + 9.4 + 15.7 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Rubicon Research LtdRUBICON | 57.6/100Mixed-positive evidence73% evidence | BREAKING OUT | 24.1/35 Revenue 46.8% · PAT 91.4% · OPM change 2 pp 100% evidence | 17.9/25 ROCE 28.4% · OPM 24% 100% evidence | 5.6/20 P/E 105× · PEG 2.63 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 24.1 + 17.9 + 5.6 + 10 = 57.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 12Marksans Pharma LtdMARKSANS | 57.4/100Mixed-positive evidence87% evidence | BREAKING OUT | 25.8/35 Revenue 19.6% · PAT 48% · OPM change 9 pp 100% evidence | 15.8/25 ROCE 18.8% · OPM 25% 100% evidence | 6.3/20 P/E 28.9× · PEG 2.85 65% evidence | 9.5/20 RS sector -18.1% · RS bench 58.3% · 1Y 95%11 of 11 weeks ahead 70% evidence |
| Exact sum: 25.8 + 15.8 + 6.3 + 9.5 = 57.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Ajanta Pharma LtdAJANTPHARM | 56.3/100Mixed-positive evidence100% evidence | BREAKING OUT | 21.3/35 Revenue 20.2% · PAT 22.2% · OPM change -1 pp 100% evidence | 19.6/25 ROCE 34.5% · OPM 26% 100% evidence | 5.5/20 P/E 38.9× · PEG 2.31 100% evidence | 9.9/20 RS sector -5.3% · RS bench 22.1% · 1Y 35.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 21.3 + 19.6 + 5.5 + 9.9 = 56.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 14Strides Pharma Science LtdSTAR | 55.9/100Mixed-positive evidence75% evidence | TURNING | 20.6/35 Revenue 8.1% · PAT 79.1% · OPM change -1 pp 95% evidence | 13.3/25 ROCE 18.3% · OPM 18% 76% evidence | 11.2/20 P/E 18.8× · PEG — 15% evidence | 10.8/20 RS sector -4.1% · RS bench 24% · 1Y 32.9%4 of 12 weeks ahead 100% evidence |
| Exact sum: 20.6 + 13.3 + 11.2 + 10.8 = 55.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Wockhardt LtdWOCKPHARMA | 54.3/100Mixed-positive evidence74% evidence | TURNING | 24.9/35 Revenue 18.4% · PAT 100% · OPM change 11 pp 74% evidence | 5.3/25 ROCE 7.5% · OPM 21% 100% evidence | 8.8/20 P/E 88.8× · PEG — 15% evidence | 15.3/20 RS sector 10.9% · RS bench 42% · 1Y 47.4%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 5.3 + 8.8 + 15.3 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16RPG Life Sciences LtdRPGLIFE | 52.6/100Mixed-positive evidence93% evidence | LEADER | 11.9/35 Revenue 11.9% · PAT -34.1% · OPM change 1 pp 100% evidence | 17.5/25 ROCE 25.7% · OPM 22% 100% evidence | 11.1/20 P/E 38.2× · PEG 1.43 65% evidence | 12.1/20 RS sector -8.1% · RS bench 19.1% · 1Y 13.5%11 of 12 weeks ahead 100% evidence |
| Exact sum: 11.9 + 17.5 + 11.1 + 12.1 = 52.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17ERIS Lifesciences LtdERIS | 52.6/100Mixed-positive evidence76% evidence | BASING | 20.4/35 Revenue 9.6% · PAT 62.2% · OPM change -2 pp 95% evidence | 14.3/25 ROCE 14.1% · OPM 34% 76% evidence | 11.9/20 P/E 28.6× · PEG — 50% evidence | 6.0/20 RS sector -13.8% · RS bench -5% · 1Y -21.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.4 + 14.3 + 11.9 + 6 = 52.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Akums Drugs & Pharmaceuticals LtdAKUMS | 51.3/100Mixed-positive evidence75% evidence | LEADER | 13.2/35 Revenue 9.2% · PAT -15.8% · OPM change 2 pp 95% evidence | 10.9/25 ROCE 14.9% · OPM 15% 76% evidence | 9.6/20 P/E 40× · PEG — 15% evidence | 17.6/20 RS sector 15.9% · RS bench 48% · 1Y 68.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.2 + 10.9 + 9.6 + 17.6 = 51.3 · Decision use: Price leads the evidence: RS versus the benchmark is 48%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 19Suven Life Sciences LtdSUVEN | 51.0/100Mixed-positive evidence67% evidence | LEADER | 19.8/35 Revenue 25% · PAT -80% · OPM change -997 pp 74% evidence | 2.2/25 ROCE -79.5% · OPM — 84% evidence | 10.0/20 P/E — · PEG — 0% evidence | 19.0/20 RS sector 29.3% · RS bench 63% · 1Y 60%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 2.2 + 10 + 19 = 51 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Zydus Lifesciences LtdZYDUSLIFE | 49.3/100Mixed-negative evidence100% evidence | FADING | 11.9/35 Revenue 21.1% · PAT -2.5% · OPM change -8 pp 100% evidence | 16.7/25 ROCE 21.1% · OPM 24% 100% evidence | 13.7/20 P/E 22.9× · PEG 1.23 100% evidence | 7.0/20 RS sector -11.7% · RS bench 14.3% · 1Y 10.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 11.9 + 16.7 + 13.7 + 7 = 49.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 21J B Chemicals & Pharmaceuticals LtdJBCHEPHARM | 47.1/100Mixed-negative evidence96% evidence | 10.6/35 Revenue 5.9% · PAT 7.4% · OPM change -2 pp 88% evidence | 20.6/25 ROCE 25.4% · OPM 22% 100% evidence | 3.9/20 P/E 53.8× · PEG 2.34 100% evidence | 12.0/20 RS sector -0.3% · RS bench 23.5% · 1Y 40.2%3 of 4 weeks ahead to 2026-07-19 100% evidence | |
| Exact sum: 10.6 + 20.6 + 3.9 + 12 = 47.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 22Lincoln Pharmaceuticals LtdLINCOLN | 46.8/100Mixed-negative evidence87% evidence | ASLEEP | 15.1/35 Revenue 10% · PAT 11.5% · OPM change 0 pp 95% evidence | 15.3/25 ROCE 16.3% · OPM 15% 95% evidence | 10.8/20 P/E 13× · PEG — 50% evidence | 5.6/20 RS sector -15.1% · RS bench 9.9% · 1Y 11.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 15.3 + 10.8 + 5.6 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Alkem Laboratories LtdALKEM | 45.1/100Mixed-negative evidence82% evidence | ASLEEP | 14.6/35 Revenue 13.4% · PAT -5.5% · OPM change -2 pp 95% evidence | 17.4/25 ROCE 21.2% · OPM 20% 76% evidence | 11.6/20 P/E 26.8× · PEG — 50% evidence | 1.5/20 RS sector -28.5% · RS bench -6.5% · 1Y -4.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 17.4 + 11.6 + 1.5 = 45.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Aurobindo Pharma LtdAUROPHARMA | 44.8/100Mixed-negative evidence100% evidence | LEADER | 16.5/35 Revenue 9.1% · PAT 9.5% · OPM change 1 pp 100% evidence | 12.3/25 ROCE 12.9% · OPM 21% 100% evidence | 4.8/20 P/E 25.6× · PEG 2.67 100% evidence | 11.2/20 RS sector -1.3% · RS bench 26.9% · 1Y 60.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 12.3 + 4.8 + 11.2 = 44.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Sun Pharmaceutical Industries LtdSUNPHARMA | 44.2/100Mixed-negative evidence100% evidence | TURNING | 16.9/35 Revenue 11.4% · PAT 16.5% · OPM change -2 pp 100% evidence | 17.3/25 ROCE 20.5% · OPM 29% 100% evidence | 4.3/20 P/E 35× · PEG 3.8 100% evidence | 5.7/20 RS sector -19.4% · RS bench 4.7% · 1Y 15.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 17.3 + 4.3 + 5.7 = 44.2 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 26Kilitch Drugs (India) LtdKILITCH | 44.1/100Mixed-negative evidence87% evidence | FADING | 13.9/35 Revenue 14% · PAT 9.3% · OPM change -1 pp 95% evidence | 9.2/25 ROCE 13.4% · OPM 6.5% 95% evidence | 14.2/20 P/E 21.6× · PEG — 50% evidence | 6.8/20 RS sector -15.6% · RS bench 10% · 1Y 0.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 9.2 + 14.2 + 6.8 = 44.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 27Gufic BioSciences LtdGUFICBIO | 44.0/100Mixed-negative evidence94% evidence | BREAKING OUT | 23.1/35 Revenue 16.6% · PAT 17.7% · OPM change 3 pp 100% evidence | 9.8/25 ROCE 12.3% · OPM 18% 100% evidence | 2.3/20 P/E 58× · PEG 4.78 100% evidence | 8.8/20 RS sector -18.4% · RS bench 26.1% · 1Y 19.2%11 of 11 weeks ahead 70% evidence |
| Exact sum: 23.1 + 9.8 + 2.3 + 8.8 = 44 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Alembic Pharmaceuticals LtdAPLLTD | 43.7/100Mixed-negative evidence94% evidence | BREAKING OUT | 16.4/35 Revenue 14.1% · PAT 14.6% · OPM change -1 pp 100% evidence | 8.4/25 ROCE 12.6% · OPM 15% 100% evidence | 12.5/20 P/E 21.4× · PEG 1.74 100% evidence | 6.4/20 RS sector -24.1% · RS bench 1.5% · 1Y -14.3%4 of 11 weeks ahead 70% evidence |
| Exact sum: 16.4 + 8.4 + 12.5 + 6.4 = 43.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Amrutanjan Health Care LtdAMRUTANJAN | 43.2/100Mixed-negative evidence87% evidence | BASING | 13.2/35 Revenue 10.7% · PAT -1.1% · OPM change -2.9 pp 95% evidence | 14.9/25 ROCE 24.8% · OPM 6.1% 95% evidence | 14.3/20 P/E 22.8× · PEG — 50% evidence | 0.8/20 RS sector -37.2% · RS bench -17% · 1Y -36.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.2 + 14.9 + 14.3 + 0.8 = 43.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 30Mankind Pharma LtdMANKIND | 42.9/100Mixed-negative evidence100% evidence | BASING | 16.8/35 Revenue 14.2% · PAT 8% · OPM change 2 pp 100% evidence | 13.8/25 ROCE 13.5% · OPM 26% 100% evidence | 8.2/20 P/E 44.2× · PEG 2.81 100% evidence | 4.1/20 RS sector -22.9% · RS bench 0.4% · 1Y -10.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 13.8 + 8.2 + 4.1 = 42.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31FDC LtdFDC | 41.9/100Mixed-negative evidence94% evidence | ASLEEP | 12.8/35 Revenue 3.5% · PAT 8.2% · OPM change -1 pp 100% evidence | 12.9/25 ROCE 15.4% · OPM 21% 100% evidence | 11.9/20 P/E 18× · PEG 2 100% evidence | 4.3/20 RS sector -25.1% · RS bench -11.7% · 1Y -27.5%4 of 10 weeks ahead 70% evidence |
| Exact sum: 12.8 + 12.9 + 11.9 + 4.3 = 41.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32Indoco Remedies LtdINDOCO | 40.7/100Thin evidence · provisional58% evidence | TURNING | 20.2/35 Revenue 11.9% · PAT 100% · OPM change 5 pp 71% evidence | 4.4/25 ROCE 1% · OPM 9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.1/20 RS sector -32.2% · RS bench 14.2% · 1Y -3.8%7 of 10 weeks ahead 70% evidence |
| Exact sum: 20.2 + 4.4 + 10 + 6.1 = 40.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Zim Laboratories LtdZIMLAB | 39.9/100Mixed-negative evidence79% evidence | LEADER | 9.6/35 Revenue 7.5% · PAT -60.6% · OPM change -3.3 pp 71% evidence | 6.1/25 ROCE 4.8% · OPM 2.6% 95% evidence | 5.8/20 P/E 202× · PEG — 50% evidence | 18.4/20 RS sector 25.7% · RS bench 59.5% · 1Y 87.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 9.6 + 6.1 + 5.8 + 18.4 = 39.9 · Decision use: Price leads the evidence: RS versus the benchmark is 59.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 34Torrent Pharmaceuticals LtdTORNTPHARM | 39.8/100Mixed-negative evidence100% evidence | BREAKING OUT | 16.6/35 Revenue 32.9% · PAT 7.7% · OPM change 2 pp 100% evidence | 14.2/25 ROCE 15.2% · OPM 34% 100% evidence | 0.8/20 P/E 84.6× · PEG 5.11 100% evidence | 8.2/20 RS sector -7.4% · RS bench 19.5% · 1Y 39%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 14.2 + 0.8 + 8.2 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Bafna Pharmaceuticals LtdBAFNAPH | 39.8/100Mixed-negative evidence60% evidence | TURNING | 11.5/35 Revenue -3.1% · PAT -5.8% · OPM change -11.3 pp 95% evidence | 7.3/25 ROCE 11.9% · OPM 3.4% 76% evidence | 8.7/20 P/E 91.5× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 84.4% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 11.5 + 7.3 + 8.7 + 12.3 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 36Bajaj Healthcare LtdBAJAJHCARE | 37.8/100Mixed-negative evidence87% evidence | BREAKING OUT | 9.8/35 Revenue 12.3% · PAT -59.1% · OPM change 1 pp 95% evidence | 10.3/25 ROCE 11.5% · OPM 17% 95% evidence | 11.9/20 P/E 20× · PEG — 50% evidence | 5.8/20 RS sector -29.8% · RS bench -7.1% · 1Y -22.5%5 of 12 weeks ahead 100% evidence |
| Exact sum: 9.8 + 10.3 + 11.9 + 5.8 = 37.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Natco Pharma LtdNATCOPHARM | 37.3/100Mixed-negative evidence100% evidence | ASLEEP | 3.0/35 Revenue -20.8% · PAT -32.5% · OPM change -18 pp 100% evidence | 14.1/25 ROCE 17.4% · OPM 25% 100% evidence | 19.1/20 P/E 12.8× · PEG 0.76 100% evidence | 1.1/20 RS sector -31.6% · RS bench -10.9% · 1Y -4.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 3 + 14.1 + 19.1 + 1.1 = 37.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 38Biocon LtdBIOCON | 36.2/100Mixed-negative evidence100% evidence | ASLEEP | 13.3/35 Revenue 9.8% · PAT -36.4% · OPM change 1 pp 100% evidence | 7.7/25 ROCE 3.6% · OPM 20% 100% evidence | 11.5/20 P/E 87.5× · PEG 0.82 100% evidence | 3.7/20 RS sector -22.1% · RS bench 1.3% · 1Y 7.4%6 of 12 weeks ahead 100% evidence |
| Exact sum: 13.3 + 7.7 + 11.5 + 3.7 = 36.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39Bharat Parenterals LtdBPLPHARMA | 35.8/100Thin evidence · provisional58% evidence | 12.3/35 Revenue -11.2% · PAT 16% · OPM change -2.8 pp 71% evidence | 4.1/25 ROCE -1.9% · OPM 9.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.4/20 RS sector -12.8% · RS bench 24.2% · 1Y 10.6%1 of 12 weeks ahead 70% evidence | |
| Exact sum: 12.3 + 4.1 + 10 + 9.4 = 35.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 40Cipla LtdCIPLA | 32.6/100Adverse evidence100% evidence | BASING | 4.6/35 Revenue 1.8% · PAT -37.7% · OPM change -9 pp 100% evidence | 12.3/25 ROCE 15.5% · OPM 17% 100% evidence | 12.0/20 P/E 30.8× · PEG 1.25 100% evidence | 3.7/20 RS sector -25.3% · RS bench -2.3% · 1Y -12.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 4.6 + 12.3 + 12 + 3.7 = 32.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Dr Reddys Laboratories Ltdthis pageDRREDDY | 30.1/100Adverse evidence100% evidence | BASING | 3.7/35 Revenue -0.9% · PAT -44.6% · OPM change -14 pp 100% evidence | 11.7/25 ROCE 13% · OPM 11% 100% evidence | 13.3/20 P/E 30.2× · PEG 1.15 100% evidence | 1.4/20 RS sector -28% · RS bench -5.9% · 1Y -8.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 3.7 + 11.7 + 13.3 + 1.4 = 30.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 42Influx Healthtech LtdINFLUX | 59.8/100Thin evidence · provisional50% evidence | TURNING | 19.3/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 20.8/25 ROCE 40% · OPM 19% 95% evidence | 10.3/20 P/E 30.5× · PEG — 15% evidence | 9.4/20 RS sector -9.8% · RS bench 16% · 1Y 43.4%10 of 12 weeks ahead 70% evidence |
| Exact sum: 19.3 + 20.8 + 10.3 + 9.4 = 59.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43Syncom Healthcare LtdSYNCOM | 49.7/100Thin evidence · provisional31% evidence | 17.1/35 Revenue -69.4% · PAT 63.5% · OPM change — 16% evidence | 6.9/25 ROCE -20.2% · OPM -225.7% 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.7/20 RS sector 29.1% · RS bench 45.7% · 1Y —9 of 12 weeks ahead to 2021-06-30 70% evidence | |
| Exact sum: 17.1 + 6.9 + 10 + 15.7 = 49.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 44Sai Parenterals LtdSAIPARENT | 37.4/100Thin evidence · provisional38% evidence | ASLEEP | 13.7/35 Revenue — · PAT — · OPM change -1 pp 32% evidence | 5.1/25 ROCE 5.3% · OPM 13.2% 95% evidence | 8.6/20 P/E 111× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —6 of 9 weeks ahead 0% evidence |
| Exact sum: 13.7 + 5.1 + 8.6 + 10 = 37.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Dr Reddys Laboratories Ltd's share price today?
Dr Reddys Laboratories Ltd trades at ₹1,166, −11.5% over the past year. The company is valued at ₹97,282 Cr. The stock sits at 8% of its 52-week range of ₹1,148–₹1,374, −5.9% versus its 200-day average. On the tape, the price is in a downtrend, 6 weeks in. — as of 11 September 2026.
What were Dr Reddys Laboratories Ltd's latest quarterly results?
Dr Reddys Laboratories Ltd reported revenue of ₹8,100 Cr and net profit of ₹436 Cr for the Jun 26 quarter. Revenue fell 5.5% and profit fell 69.1% year on year. Earnings per share were ₹5.32. The operating margin was 11.0%, 14.0 pp lower than a year earlier. — as of 11 September 2026.
What is Dr Reddys Laboratories Ltd's revenue?
Dr Reddys Laboratories Ltd reported revenue of ₹8,100 Cr in the Jun 26 quarter, −5.5% year on year. For the full FY26 fiscal year, revenue was ₹33,700 Cr (+3.2%). Over the last 10 years revenue compounded at 8.0% a year. — as of 11 September 2026.
What is Dr Reddys Laboratories Ltd's profit?
Dr Reddys Laboratories Ltd earned ₹436 Cr of net profit in the Jun 26 quarter, −69.1% year on year. Full-year FY26 profit was ₹4,158 Cr. The operating margin ran 11.0% in the latest quarter. — as of 11 September 2026.
What is Dr Reddys Laboratories Ltd's market cap?
Dr Reddys Laboratories Ltd's market capitalisation is ₹97,282 Cr at a share price of ₹1,166. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Dr Reddys Laboratories Ltd's P/E ratio?
Dr Reddys Laboratories Ltd trades at a P/E of 30.2×, at the 60th percentile of its own 11-year range, against a long-run median of 25.9×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Dr Reddys Laboratories Ltd pay a dividend?
Yes — Dr Reddys Laboratories Ltd's dividend payout was 16% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Dr Reddys Laboratories Ltd overvalued?
On its own history, Dr Reddys Laboratories Ltd looks mid-range: its P/E of 30.2× sits at the 60th percentile of its 11-year range (long-run median 25.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Dr Reddys Laboratories Ltd growing?
Not right now — Dr Reddys Laboratories Ltd's latest numbers are shrinking: latest-quarter revenue −5.5% year on year, profit −69.1%, and the margin −14.0 pp at 11.0%. The 10-year compound rates are 8.0% (revenue) and 6.9% (profit). The earnings engine currently reads: deteriorating — as of 11 September 2026.
How is Dr Reddys Laboratories Ltd performing?
Dr Reddys Laboratories Ltd is in a downtrend, 6 weeks in. Its latest quarter's revenue fell 5.5% and profit fell 69.1% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 11 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Dr Reddys Laboratories Ltd in?
Deteriorating — profit and EPS growth are shrinking (profit growth −44.6% latest against +64.4% at its 12-quarter best), ROCE slipping at 11.2%. The read comes from the last 12 quarters of growth (revenue growth −0.9% latest, profit growth −44.6% latest, eps growth −43.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Dr Reddys Laboratories Ltd in an uptrend?
No — the price is in a downtrend (week 6 of stage 4), trading −5.9% versus its 200-day average and at 8% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Dr Reddys Laboratories Ltd beating the market?
Not lately — on a trailing-13-week view Dr Reddys Laboratories Ltd is currently behind the NIFTY 500 (11 weeks and counting; last ahead the week of 2026-07-01), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +79% against the NIFTY 500's +264% — behind the index over the full window. — as of 11 September 2026.
Will Dr Reddys Laboratories Ltd's share price go up?
This page publishes no price forecast for Dr Reddys Laboratories Ltd. What it measures instead: the share price is ₹1,166, the price is in a downtrend 6 weeks in. Its P/E of 30.2× sits at the 60th percentile of its own 11-year range. — as of 11 September 2026.
Who owns Dr Reddys Laboratories Ltd?
Promoters hold 26.6% of Dr Reddys Laboratories Ltd, foreign institutions 20.7%, domestic institutions 31.8% and the public 20.8% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 11.0 points over 8 quarters. — as of 11 September 2026.
Does Dr Reddys Laboratories Ltd have too much debt?
No — Dr Reddys Laboratories Ltd's debt-to-equity is 0.20, and operating profit covers the interest bill 17×. FY26 borrowings were ₹7,734 Cr against equity of ₹37,892 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Dr Reddys Laboratories Ltd's capex?
Dr Reddys Laboratories Ltd spent ₹18,507 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹4,890 Cr, with ₹1,460 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Dr Reddys Laboratories Ltd's cash flow?
Dr Reddys Laboratories Ltd generated ₹5,674 Cr of operating cash flow in FY26 and ₹784 Cr of free cash flow after ₹4,890 Cr of capital spending. Reported profit that year was ₹4,158 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Dr Reddys Laboratories Ltd's profit real cash?
Yes — over the last 3 fiscal years, 96% of Dr Reddys Laboratories Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹5,674 Cr against reported profit of ₹4,158 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
How financially safe is Dr Reddys Laboratories Ltd?
On the balance sheet, the Z-score reads 5.29 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 11 September 2026.
Where is Dr Reddys Laboratories Ltd in its business cycle?
Dr Reddys Laboratories Ltd's FY26 operating margin was 19.0%, against a 13-year band of 14.0%–28.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 11.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Dr Reddys Laboratories Ltd's price assume?
At its price on 29 June 2026, Dr Reddys Laboratories Ltd was priced for profit growth of about 17.5% a year. Profit itself has compounded 6.9% a year over the past 10 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Dr Reddys Laboratories Ltd story?
The sharpest disagreement: Domestic institutions moved +11.0 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Dr Reddys Laboratories Ltd a stock worth studying right now?
This is not investment advice. The machine read: Dr Reddys Laboratories Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the register turns back in the story’s favour. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!